Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

@article{Arpino2005EstrogenRP,
  title={Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.},
  author={Grazia Arpino and Heidi Weiss and Adrian V. Lee and Rachel Schiff and Sabino de Placido and Charles Osborne and Richard M. Elledge},
  journal={Journal of the National Cancer Institute},
  year={2005},
  volume={97 17},
  pages={1254-61}
}
BACKGROUND Clinical data indicate that estrogen receptor-positive/progesterone receptor-negative (ER+/PR-) breast cancers are less sensitive to tamoxifen than are ER+/PR+ tumors. It has also been reported that tamoxifen may be less effective in tumors that overexpress either HER-2 or HER-1 (epidermal growth factor receptor) and that signaling through these receptors reduces PR expression in experimental models. We hypothesized that ER+/PR- breast tumors are more likely than ER+/PR+ breast… CONTINUE READING